Tuesday, January 9, 2007 7:30:00 AM PDT | VentureDeal Staff
PLEASANTON, CA -- Juvaris BioTherapeutics announced that it has closed its first series A round of $6 million. The company expects to close another $6 million within 120 days, to bring the total series A to $12 million. The company is developing an immunotherapeutic platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. The investment came from the Kleiner Perkins Caufield & Byers Pandemic & Biodefense Fund, which is a purpose-driven fund that focuses its investments on treatments or vaccines for pandemics.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
